Development of a Radiomic-Based Model Predicting Lymph Node Involvement in Prostate Cancer Patients.

MRI lymph node involvement prediction prostate cancer radiomics

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
12 Nov 2021
Historique:
received: 23 09 2021
revised: 31 10 2021
accepted: 08 11 2021
entrez: 27 11 2021
pubmed: 28 11 2021
medline: 28 11 2021
Statut: epublish

Résumé

Significant advances in lymph node involvement (LNI) risk modeling in prostate cancer (PCa) have been achieved with the addition of visual interpretation of magnetic resonance imaging (MRI) data, but it is likely that quantitative analysis could further improve prediction models. In this study, we aimed to develop and internally validate a novel LNI risk prediction model based on radiomic features extracted from preoperative multimodal MRI. All patients who underwent a preoperative MRI and radical prostatectomy with extensive lymph node dissection were retrospectively included in a single institution. Patients were randomly divided into the training (60%) and testing (40%) sets. Radiomic features were extracted from the index tumor volumes, delineated on the apparent diffusion coefficient corrected map and the T2 sequences. A ComBat harmonization method was applied to account for inter-site heterogeneity. A prediction model was trained using a neural network approach (Multilayer Perceptron Network, SPSS v24.0©) combining clinical, radiomic and all features. It was then evaluated on the testing set and compared to the current available models using the Receiver Operative Characteristics and the C-Index. Two hundred and eighty patients were included, with a median age of 65.2 y (45.3-79.6), a mean PSA level of 9.5 ng/mL (1.04-63.0) and 79.6% of ISUP ≥ 2 tumors. LNI occurred in 51 patients (18.2%), with a median number of extracted nodes of 15 (10-19). In the testing set, with their respective cutoffs applied, the Partin, Roach, Yale, MSKCC, Briganti 2012 and 2017 models resulted in a C-Index of 0.71, 0.66, 0.55, 0.67, 0.65 and 0.73, respectively, while our proposed combined model resulted in a C-Index of 0.89 in the testing set. Radiomic features extracted from the preoperative MRI scans and combined with clinical features through a neural network seem to provide added predictive performance compared to state of the art models regarding LNI risk prediction in PCa.

Identifiants

pubmed: 34830828
pii: cancers13225672
doi: 10.3390/cancers13225672
pmc: PMC8616049
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Eur Urol. 2019 Mar;75(3):506-514
pubmed: 30342844
Biostatistics. 2007 Jan;8(1):118-27
pubmed: 16632515
J Clin Oncol. 2021 Apr 10;39(11):1234-1242
pubmed: 33497252
Eur Urol. 2017 Oct;72(4):632-640
pubmed: 28412062
Eur Urol. 2020 Jan;77(1):3-10
pubmed: 30992160
Eur Urol. 2017 Jul;72(1):84-109
pubmed: 28126351
Eur Radiol. 2015 Oct;25(10):2840-50
pubmed: 25991476
World J Urol. 2021 May;39(5):1489-1497
pubmed: 32583038
Int J Radiat Oncol Biol Phys. 1994 Jan 1;28(1):33-7
pubmed: 7505775
Cancers (Basel). 2020 Mar 28;12(4):
pubmed: 32231077
Urol Oncol. 2020 Nov;38(11):847.e9-847.e16
pubmed: 32466877
Front Oncol. 2019 Aug 27;9:807
pubmed: 31508367
Neuroimage. 2018 Feb 15;167:104-120
pubmed: 29155184
Rev Urol. 2016;18(1):1-9
pubmed: 27162506
J Urol. 2018 Nov;200(5):1022-1029
pubmed: 29886090
N Engl J Med. 2020 Mar 5;382(10):917-928
pubmed: 32130814
Rev Urol. 2010 Winter;12(1):20-4
pubmed: 20428290
Jpn J Radiol. 2018 Apr;36(4):257-272
pubmed: 29498017
Radiology. 2020 May;295(2):328-338
pubmed: 32154773
Eur Urol. 2006 Nov;50(5):1006-13
pubmed: 16959399
Eur Urol. 2013 Jun;63(6):998-1008
pubmed: 23122664
Int J Radiat Oncol Biol Phys. 2016 Nov 15;96(4):759-769
pubmed: 27788949
Eur Urol. 2019 Sep;76(3):340-351
pubmed: 30898406
Eur Urol. 2012 Mar;61(3):480-7
pubmed: 22078338
Int J Radiat Oncol Biol Phys. 2011 May 1;80(1):69-75
pubmed: 20594769
N Engl J Med. 2018 May 10;378(19):1767-1777
pubmed: 29552975
Eur Urol. 2007 Jul;52(1):29-37
pubmed: 17448592
Eur Urol. 2011 Aug;60(2):195-201
pubmed: 21257258
Eur Urol Oncol. 2019 Sep;2(5):541-548
pubmed: 31411992
Eur Urol. 2020 Aug;78(2):138-142
pubmed: 32268944
Curr Probl Diagn Radiol. 2020 Nov - Dec;49(6):365-367
pubmed: 31326143
Eur Urol Oncol. 2021 Aug;4(4):532-539
pubmed: 33865797
Radiology. 2018 May;287(2):534-542
pubmed: 29361246
BJU Int. 2017 May;119(5):676-683
pubmed: 27367645
Nat Rev Clin Oncol. 2017 Dec;14(12):749-762
pubmed: 28975929

Auteurs

Vincent Bourbonne (V)

Radiation Oncology Department, University Hospital, 29200 Brest, France.
LaTIM, UMR 1101, INSERM, University Brest, 29200 Brest, France.

Vincent Jaouen (V)

LaTIM, UMR 1101, INSERM, University Brest, 29200 Brest, France.
IMT Atlantique, 29200 Brest, France.

Truong An Nguyen (TA)

LaTIM, UMR 1101, INSERM, University Brest, 29200 Brest, France.
Urology Department, University Hospital, 29200 Brest, France.

Valentin Tissot (V)

Radiology Department, University Hospital, 29200 Brest, France.

Laurent Doucet (L)

Pathology Department, University Hospital, 29200 Brest, France.

Mathieu Hatt (M)

LaTIM, UMR 1101, INSERM, University Brest, 29200 Brest, France.

Dimitris Visvikis (D)

LaTIM, UMR 1101, INSERM, University Brest, 29200 Brest, France.

Olivier Pradier (O)

Radiation Oncology Department, University Hospital, 29200 Brest, France.
LaTIM, UMR 1101, INSERM, University Brest, 29200 Brest, France.

Antoine Valéri (A)

LaTIM, UMR 1101, INSERM, University Brest, 29200 Brest, France.
Urology Department, University Hospital, 29200 Brest, France.

Georges Fournier (G)

LaTIM, UMR 1101, INSERM, University Brest, 29200 Brest, France.
Urology Department, University Hospital, 29200 Brest, France.

Ulrike Schick (U)

Radiation Oncology Department, University Hospital, 29200 Brest, France.
LaTIM, UMR 1101, INSERM, University Brest, 29200 Brest, France.

Classifications MeSH